Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance.

Anisuzzaman AS, Haque A, Wang D, Rahman MA, Zhang C, Chen Z, Chen ZG, Shin DM, Amin AR.

Mol Cancer Ther. 2017 Apr;16(4):729-738. doi: 10.1158/1535-7163.MCT-16-0683. Epub 2017 Jan 23.

2.

Activation of muscarinic cholinoceptor ameliorates tumor necrosis factor-α-induced barrier dysfunction in intestinal epithelial cells.

Khan MR, Uwada J, Yazawa T, Islam MT, Krug SM, Fromm M, Karaki S, Suzuki Y, Kuwahara A, Yoshiki H, Sada K, Muramatsu I, Anisuzzaman AS, Taniguchi T.

FEBS Lett. 2015 Nov 30;589(23):3640-7. doi: 10.1016/j.febslet.2015.10.029. Epub 2015 Oct 28.

3.

Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers.

Anisuzzaman AS, Haque A, Rahman MA, Wang D, Fuchs JR, Hurwitz S, Liu Y, Sica G, Khuri FR, Chen ZG, Shin DM, Amin AR.

Cancer Prev Res (Phila). 2016 Jan;9(1):63-73. doi: 10.1158/1940-6207.CAPR-15-0240. Epub 2015 Oct 28.

4.

Muscarinic cholinoceptor-mediated activation of JNK negatively regulates intestinal secretion in mice.

Khan MR, Islam MT, Yazawa T, Hayashi H, Suzuki Y, Uwada J, Anisuzzaman AS, Taniguchi T.

J Pharmacol Sci. 2015 Jan;127(1):150-3. doi: 10.1016/j.jphs.2014.10.001. Epub 2014 Nov 14.

5.

Pharmacologically distinct phenotypes of α1B -adrenoceptors: variation in binding and functional affinities for antagonists.

Yoshiki H, Uwada J, Anisuzzaman AS, Umada H, Hayashi R, Kainoh M, Masuoka T, Nishio M, Muramatsu I.

Br J Pharmacol. 2014 Nov;171(21):4890-901. doi: 10.1111/bph.12813. Epub 2014 Sep 5.

6.

Activation of focal adhesion kinase via M1 muscarinic acetylcholine receptor is required in restitution of intestinal barrier function after epithelial injury.

Khan RI, Yazawa T, Anisuzzaman AS, Semba S, Ma Y, Uwada J, Hayashi H, Suzuki Y, Ikeuchi H, Uchino M, Maemoto A, Muramatsu I, Taniguchi T.

Biochim Biophys Acta. 2014 Apr;1842(4):635-45. doi: 10.1016/j.bbadis.2013.12.007. Epub 2013 Dec 21.

7.

Comparison of subcellular distribution and functions between exogenous and endogenous M1 muscarinic acetylcholine receptors.

Morishima S, Anisuzzaman ASM, Uwada J, Yoshiki H, Muramatsu I.

Life Sci. 2013 Jul 19;93(1):17-23. doi: 10.1016/j.lfs.2013.05.013. Epub 2013 May 30.

PMID:
23727356
8.

Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus.

Anisuzzaman AS, Uwada J, Masuoka T, Yoshiki H, Nishio M, Ikegaya Y, Takahashi N, Matsuki N, Fujibayashi Y, Yonekura Y, Momiyama T, Muramatsu I.

J Neurochem. 2013 Aug;126(3):360-71. doi: 10.1111/jnc.12306. Epub 2013 Jun 9.

9.

M1 is a major subtype of muscarinic acetylcholine receptors on mouse colonic epithelial cells.

Khan MR, Anisuzzaman AS, Semba S, Ma Y, Uwada J, Hayashi H, Suzuki Y, Takano T, Ikeuchi H, Uchino M, Maemoto A, Ushikubi F, Muramatsu I, Taniguchi T.

J Gastroenterol. 2013 Aug;48(8):885-96. doi: 10.1007/s00535-012-0718-5. Epub 2012 Dec 15.

PMID:
23242454
10.

Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways.

Ikeda T, Anisuzzaman AS, Yoshiki H, Sasaki M, Koshiji T, Uwada J, Nishimune A, Itoh H, Muramatsu I.

Br J Pharmacol. 2012 Jul;166(6):1804-14. doi: 10.1111/j.1476-5381.2012.01881.x.

11.

Re-evaluation of nicotinic acetylcholine receptors in rat brain by a tissue-segment binding assay.

Wang MH, Yoshiki H, Anisuzzaman AS, Uwada J, Nishimune A, Lee KS, Taniguchi T, Muramatsu I.

Front Pharmacol. 2011 Oct 19;2:65. doi: 10.3389/fphar.2011.00065. eCollection 2011.

12.

Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

Nishimune A, Yoshiki H, Uwada J, Anisuzzaman AS, Umada H, Muramatsu I.

Br J Pharmacol. 2012 Mar;165(5):1226-34. doi: 10.1111/j.1476-5381.2011.01591.x. Review.

13.

Intracellular distribution of functional M(1) -muscarinic acetylcholine receptors in N1E-115 neuroblastoma cells.

Uwada J, Anisuzzaman AS, Nishimune A, Yoshiki H, Muramatsu I.

J Neurochem. 2011 Sep;118(6):958-67. doi: 10.1111/j.1471-4159.2011.07378.x. Epub 2011 Aug 5.

14.

Assessment of novel muscarinic acetylcholine receptors in rat cerebral cortex by a tissue segment binding method.

Lee KS, Nishimune A, Yoshiki H, Anisuzzaman AS, Suzuki F, Wang MH, Cheng JT, Muramatsu I.

J Pharmacol Sci. 2010;112(4):444-51.

15.

Expression of distinct alpha 1-adrenoceptor phenotypes in the iris of pigmented and albino rabbits.

Muramatsu I, Suzuki F, Nishimune A, Anisuzzaman AS, Yoshiki H, Su TH, Chang CK, Morishima S.

Br J Pharmacol. 2009 Sep;158(1):354-60. doi: 10.1111/j.1476-5381.2009.00254.x. Epub 2009 May 12.

16.

Identification of M(1) muscarinic receptor subtype in rat stomach using a tissue segment binding method, and the effects of immobilization stress on the muscarinic receptors.

Anisuzzaman AS, Morishima S, Suzuki F, Tanaka T, Muramatsu I.

Eur J Pharmacol. 2008 Dec 3;599(1-3):146-51. doi: 10.1016/j.ejphar.2008.10.008. Epub 2008 Oct 10.

PMID:
18938154
17.

Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout.

Muramatsu I, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T, Rodrigo MC, Myagmar BE, Simpson PC.

Br J Pharmacol. 2008 Dec;155(8):1224-34. doi: 10.1038/bjp.2008.360. Epub 2008 Sep 22.

18.

Native profiles of alpha(1A)-adrenoceptor phenotypes in rabbit prostate.

Su TH, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T, Cheng JT, Muramatsu I.

Br J Pharmacol. 2008 Nov;155(6):906-12. doi: 10.1038/bjp.2008.318. Epub 2008 Aug 11.

19.

Different affinities of native alpha1B-adrenoceptors for ketanserin between intact tissue segments and membrane preparations.

Sathi ZS, Anisuzzaman AS, Morishima S, Suzuki F, Tanaka T, Yoshiki H, Muramatsu I.

Eur J Pharmacol. 2008 Apr 28;584(2-3):222-8. doi: 10.1016/j.ejphar.2008.02.003. Epub 2008 Feb 12.

PMID:
18336813
20.

Assessment of muscarinic receptor subtypes in human and rat lower urinary tract by tissue segment binding assay.

Anisuzzaman AS, Morishima S, Suzuki F, Tanaka T, Yoshiki H, Sathi ZS, Akino H, Yokoyama O, Muramatsu I.

J Pharmacol Sci. 2008 Feb;106(2):271-9. Epub 2008 Feb 9.

21.

Quantifying receptor properties: the tissue segment binding method - a powerful tool for the pharmacome analysis of native receptors.

Muramatsu I, Tanaka T, Suzuki F, Li Z, Hiraizumi-Hiraoka Y, Anisuzzaman AS, Yamamoto H, Horinouchi T, Morishima S.

J Pharmacol Sci. 2005 Aug;98(4):331-9. Epub 2005 Aug 5. Review.

Supplemental Content

Loading ...
Support Center